1 / 12

Development of ARV FDC for Pediatric use

Development of ARV FDC for Pediatric use. Alan Parr, Pharm.D., Ph.D. GlaxoSmithKline Research Triangle Park, NC. Presentation Outline. Introduction Physical/Chemical considerations Formulation consideration Packaging considerations Conclusions. Introduction.

maina
Télécharger la présentation

Development of ARV FDC for Pediatric use

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Development of ARV FDC for Pediatric use Alan Parr, Pharm.D., Ph.D. GlaxoSmithKline Research Triangle Park, NC

  2. Presentation Outline • Introduction • Physical/Chemical considerations • Formulation consideration • Packaging considerations • Conclusions E://presentations/WHO110304a

  3. Introduction • Development of formulations for pediatric population is very challenging for the following reasons: • Requires a wide range of doses (not achievable using solid dosage forms) • Limited patient populations to evaluate efficacy of compound/product • Difficulty in doing studies in this patient population • Potential biological differences (e.g., metabolic differences) between pediatric patients and adult patients E://presentations/WHO110304a

  4. Overall Formulation considerations for Pediatric Formulations • Need to be aware of taste preference which differ significantly around the world • Need to be aware of sweetness preferences which differ from around the world • Need to be aware of the limit of inactive ingredients administered per the dosing regimen E://presentations/WHO110304a

  5. Physical/Chemical considerations for Pediatric formulations • Solubility of drug substance • Stability of the drug substance in solution • Compatibility of drug substance with excipients (e.g., flavors, sweeteners, preservatives) • Stability of multiple drug substances in a given formulation E://presentations/WHO110304a

  6. Formulation consideration for Pediatric formulations (Chemical basis) • Chemical stability of the drug substance • Chemical stability of the preservative system • Chemical stability of flavor and sweetening system • Impact of the buffering system on drug substance stability E://presentations/WHO110304a

  7. Formulation consideration for Pediatric formulations (Physical basis) • Loss of taste (e.g., sweetness and flavor) • pH of the product • Viscosity of the product • Change of color of the product • Mouth feel E://presentations/WHO110304a

  8. Packaging considerations for Pediatric formulations • Compatibility of packaging components with: • The drug substance • The preservatives • The flavors and sweeteners • The pH and buffering system • Absorption or adsorption of drug and inactive ingredients • Amount and type of leachables • Headspace in the container E://presentations/WHO110304a

  9. Conclusions • Development of a pediatric formulation is very challenging and complex • It requires a balance between a number of different variables to ensure a consistent product with appropriate stability, preservative system, and acceptable taste E://presentations/WHO110304a

  10. Back-up Slides E://presentations/WHO110304a

  11. Available Formulations that could be used in Pediatric Patients • Abacavir (Ziagen®) Pediatric Oral Solution (GSK) • Didanosine (Videx®) Pediatric Powder (BMS) • Lamivudine (Epivir®) Oral Solution (GSK) • Stavudine (Zerit®) Oral Solution (BMS) • Zidovudine (Retrovir®) Syrup (GSK) • Nevirapine (Viramune®) Suspension (BI) • Amprenavir (Agenerase®) Pediatric Oral Solution (GSK) • Fosamprenavir (Lexiva®) Suspension* (GSK) • Lopinavir/Ritonavir (Kaletra®) Pediatric Oral Solution (Abbott) • Nelfinavir (Viracept®) Powder for Oral Suspension (Agouron/Pfizer) • Ritonavir (Norvir®) Oral Solution (Abbott) * Under development E://presentations/WHO110304a

  12. Formulation Options for Pediatric patients • Oral solutions • Oral suspensions • Sachets • Note: need to re-constitute with a specific volume of liquid to dose on a mg/kg or mg/m2 E://presentations/WHO110304a

More Related